Search This Blog

Tuesday, November 17, 2026

Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial, Eyes FDA Filing In First Half Of 2027

 

  • Sellas said the treatment was generally well tolerated, with no new safety concerns.

  • Most treatment-related side effects were mild or moderate, with reactions mainly at the injection site, the company said.

  • Sellas said the results were statistically significant, with a hazard ratio of 0.59

Sellas Life Sciences (SLS) said on Tuesday that its experimental cancer vaccine, Galinpepimut-S (GPS), significantly improved overall survival in patients with acute myeloid leukemia (AML), with the biotech firm eyeing a potential regulatory filing in the first half of next year.

The company announced that its pivotal Phase 3 Regal trial met its primary goal, with GPS reducing the risk of death by 41% compared with the best available treatment (BAT). The trial also showed a median overall survival (OS) of 24 months, compared with 14.7 months for those receiving BAT.

https://finance.yahoo.com/healthcare/articles/sellas-gps-cuts-death-risk-125915492.html

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.